A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma

NCT06776952 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Peripheral T Cell Lymphoma

Interventions

DRUG: XNW5004 ; Chidamide placebo
DRUG: XNW5004 placebo; Chidamide

Sponsor

Evopoint Biosciences Inc.